Celldex Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview

Celldex Therapeutics

30/04/2024 12:41

* Celldex Therapeutics Inc  CLDX.OQ   CLDX.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 2
(estimated) for the period ending March 31 2024
    * The Hampton New Jersey-based  company is expected to
report a
5.3% decrease in revenue to $915.75 thousand from $967 thousand
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Celldex Therapeutics Inc
is
for a loss of 69 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 2.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $77.00​, above​ its last closing price
of $37.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.76       -0.74      -0.83     Missed  -11.6
 Jan. 1 2023   -0.68       -0.68      -0.81     Missed  -19.4
 Jun. 30 2023  -0.67       -0.67      -0.65     Beat    2.5​
 Jan. 1 0001   -0.63       -0.63                        1.9
 ​​Dec.        -0.59       -0.59                        5.1
 31 2022                                                
 Sep. 30 2022  -0.57       -0.58      -0.57     Beat    1.2​
 Jan. 1 0001   -0.51       -0.51      -0.59     Missed  -15.7
 Jan. 1 0001   -0.45       -0.45      -0.49     Missed  -7.9
 This summary was machine generated April 30 at 11:41 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)